Showing 1521-1530 of 3092 results for "".
Update: Oral Therapies for the Treatment of BCC
https://practicaldermatology.com/topics/practice-management/update-oral-therapies-for-the-treatment-of-bcc/21132/With the recent FDA approval of a new oral agent, the therapeutic outlook for BCC is both more diverse and promising.In Case of Emergency…
https://practicaldermatology.com/topics/practice-management/in-case-of-emergency/21155/Social Bullying: What's Our Role in It?
https://practicaldermatology.com/topics/practice-management/social-bullying-whats-our-role-in-it/21187/Mohs Certification: A Call for Dialogue
https://practicaldermatology.com/topics/practice-management/mohs-certification-a-call-for-dialogue/21222/Recently Passed Law Clears Way for New Sunscreen Ingredients
https://practicaldermatology.com/topics/skin-cancer-photoprotection/recently-passed-law-clears-way-for-new-sunscreen-ingredients/21232/By forcing the FDA to clear its backlog of sunscreen ingredients pending review, The Sunscreen Innovation Act is a major win for UV protection efforts.New Products
https://practicaldermatology.com/columns/new-products/new-products/21262/The Molecular Era in Melanoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-molecular-era-in-melanoma-treatment/21296/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.